Medifast, Inc. (NYSE: MED) — 2022 Form 10-K
Reporting period: Fiscal year ended December 31, 2022. This is an annual filing, not a standalone fourth-quarter report. Medifast’s business is primarily its OPTA VIA health and wellness program, which sells nutrition products through a direct-to-consumer model supported by independent Coaches. OPTA VIA represented approximately 100% of 2022 revenue.
Financial performance
| Metric | 2022 | 2021 | Change |
|---|---|---|---|
| Revenue | $1,598.6 million | $1,526.1 million | +4.8% |
| Gross profit / margin | $1,140.4 million / 71.3% | $1,127.6 million / 73.9% | Profit +1.1%; margin down 2.6 percentage points |
| SG&A | $955.6 million | $911.4 million | +4.9% |
| Operating income / margin | $184.8 million / 11.6% | $216.2 million / 14.2% | -14.5%; margin down 2.6 percentage points |
| Net income | $143.6 million | $164.0 million | -12.5% |
| Diluted EPS | $12.73 | $13.89 | -8.4% |
| Operating cash flow | $194.6 million | $94.5 million | +$100.0 million |
| Cash and investment securities | $87.7 million | $109.5 million | Down $21.8 million |
Revenue growth reflected more active earning Coaches, productivity gains in the first half, and product price increases. For the quarter ended December 31, average revenue per active earning Coach fell 12.4% year over year to $5,538, which management attributed to weaker customer acquisition and consumers recalibrating spending. The filing does not provide a clear standalone fourth-quarter consolidated revenue or profit value in the supplied text.
Gross margin pressure reflected inflation in ingredients, freight and labor; promotional customer-acquisition activity; and $12.2 million of costs to restructure external manufacturing agreements. SG&A included $19.0 million of inventory donated for Ukraine relief, as well as higher Coach compensation and payment-processing costs and continued technology investment. The filing’s non-GAAP measures exclude the Ukraine donation and manufacturing restructuring costs; these are supplemental measures, not GAAP results.
Liquidity, capital allocation and debt
- Working capital was $81.9 million at year-end, down from $137.0 million in 2021. Stockholders’ equity was $155.0 million versus $202.5 million.
- Operating cash flow rose primarily because of working-capital movements, including lower inventory purchases as demand softened late in the year. Investing cash use was $11.4 million, including $16.7 million of capital expenditures.
- Financing cash use was $199.6 million, including $126.4 million of stock repurchases and $71.6 million of dividends paid. Dividends declared were $6.56 per share for 2022; a $1.64 quarterly dividend declared in December was paid in February 2023.
- No borrowings were outstanding under the $225 million senior secured revolving credit facility at December 31, 2022. The facility matures in 2026 and includes customary covenants and leverage and interest-coverage tests.
- Contractual obligations totaled $243.0 million, including $215.7 million of unconditional purchase obligations, primarily for inventory, outsourced IT and Coach events, and $27.3 million of operating lease payments.
Changes, outlook and risks
- Growth slowed sharply from 63.2% revenue growth in 2021 to 4.8% in 2022, while operating income and net income declined. Active earning Coaches increased 1.8% year over year to 60,900 at year-end, but fourth-quarter revenue per Coach weakened.
- Management identified customer acquisition, reactivation, retention and Coach tenure as priorities. Initiatives included a late-2022/early-2023 customer repeat-order program and an expanded Coach acquisition bonus for 2023. The filing gives no specific 2023 revenue or earnings guidance.
- Management cited inflation, consumer spending pressure, labor conditions and supply-chain costs. The company raised prices by an average of approximately 4.5% in November 2022, following an average increase of approximately 3.5% in December 2021.
- Key risks include dependence on independent Coaches and the direct-selling model; FTC scrutiny of compensation, testimonials and earnings claims; customer acquisition and retention; product and supply-chain disruption; competition, including potentially easier pharmaceutical weight-loss alternatives; product liability; and cybersecurity, privacy and international regulatory risks.
- The company reported ordinary-course legal claims that it did not believe would materially affect results, financial position or liquidity, while noting outcomes cannot be predicted. The auditor issued unqualified opinions on the financial statements and internal controls; income taxes were identified as a critical audit matter.
Most important facts to verify
- Confirm the trajectory of Coach productivity and customer acquisition after the fourth-quarter decline, and whether 2023 initiatives improved repeat orders and retention.
- Track gross margin recovery against inflation, pricing, promotional activity and the manufacturing-agreement restructuring.
- Assess whether operating cash flow is sustainable as inventory and payables movements normalize, and monitor working capital and purchase commitments.
- Review the sustainability of dividends and repurchases relative to cash generation and the company’s stated capital needs.
- Reconcile adjusted diluted EPS: the narrative reports $14.49, while the non-GAAP reconciliation table shows $14.50.